Mechanistic Rationales for Novel and Emerging Treatments for Psoriatic Arthritis: Plugging the Data into the Equation

CMEO Snack

Premiere Date: Monday, February 22, 2021

This activity offers CE credit for:

  1. Physicians (CME)
  2. Pharmacists (ACPE)
  3. ABIM (MOC)
  4. Other


All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Tuesday, February 22, 2022

Begin Activity Now

Faculty


Allan Gibofsky, MD, JD, MACR, FACP, FCLM
Allan Gibofsky, MD, JD, MACR, FACP, FCLM 
Professor of Medicine
Weill Cornell Medicine
Attending Rheumatologist
Co-Director, Clinic for Inflammatory Arthritis
Hospital for Special Surgery
New York, NY

Anthony Fernandez, MD, PhD
Anthony Fernandez, MD, PhD 
Director of Medical Dermatology
W.D. Steck Chair of Clinical Dermatology
Departments of Dermatology and Pathology
Dermatology and Plastic Surgery Institute
Cleveland Clinic
Cleveland, OH

Statement of Need

Psoriatic arthritis (PsA) can have serious debilitating effects on peripheral joints, the spine, tendon insertions, and fingers. Management of PsA has improved with therapies such as nonpharmacologic and symptomatic treatments, oral small molecules, tumor necrosis factor inhibitors, interleukin (IL)-12/23 inhibitors, IL-17 inhibitors, CTLA4-lg, Janus kinase (JAK)/TyK2 inhibitors, and IL-23 inhibitors; however, complete disease control has not yet been achieved.

This CME Outfitters Snack focuses on evaluating the mechanistic rationale for novel and emerging treatments for PsA as well as assessing safety and efficacy data for current and emerging JAK inhibitors to determine their role in the management of PsA in order to help narrow the treatment gap.

Learning Objectives

At the end of this CME/CE activity, participants should be able to:

  • Assess the mechanistic rationale for novel and emerging treatments for psoriatic arthritis, including key clinical efficacy and safety data for targeted treatments.

Financial Support

Supported by an educational grant from Bristol Myers Squibb Company.

Target Audience

Physicians, PAs, nurse practitioners, nurses, and pharmacists

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists (CPE):
ACPE CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .25 contact hours (0.025 CEUs) Universal Activity Number:
Enduring: 0376-0000-21-030-H01-P

Type: Knowledge-based

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .25 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Formats
Enduring material

Royal College MOC: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Note to PAs: PAs may claim a maximum of .25 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Gibofsky reports that he is on the advisory committee for AbbVie Inc.; Aurinia Pharmaceuticals Inc.; Eli Lilly and Company; Gilead Sciences, Inc.; Novartis; Pfizer Inc.; and Samumed. He is a consultant for AbbVie Inc.; Acquist Therapeutics, Inc.; Amgen Inc.; Eli Lilly and Company; Gilead Sciences, Inc.; Novartis; Pfizer Inc.; and Samumed. He is a stock shareholder (directly purchased) for AbbVie Inc.; Johnson & Johnson; Pfizer Inc.; and Regeneron Pharmaceuticals, Inc.

Dr. Fernandez reports that he receives grants from Mallinckrodt and Novartis. He receives research support from AbbVie Inc.; Corbus Pharmaceuticals Holdings, Inc.; Mallinckrodt Pharmaceuticals; and Pfizer Inc. He is on the speakers bureau for AbbVie Inc.; Mallinckrodt Pharmaceuticals; and Novartis. He is a consultant for AbbVie Inc.; Alexion Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Mallinckrodt Pharmaceuticals; and Novartis.

Tony Graham, MD (peer reviewer) has no disclosures to report.

Michael J. Franks, MSN, AGACNP-BC, FNP, BC (peer reviewer) has no disclosures to report.

Susan Perry (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

CME Outfitters, LLC and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


This document was last modified on:

SN-135-022221-08